Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy (NatHis-SMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

NatHis-SMA is a prospective, longitudinal and interventional study of the natural history of patients with type 2 and 3 Spinal Muscular Atrophy (SMA). The purpose of this study is to characterize the disease course over 2 years and identify prognostic variables of the disease and biomarkers of SMA progression, as well as determine the best outcome measures for further therapeutics approaches.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

2 Years to 30 Years (Child, Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

INCLUSION CRITERIA

Type 2 or 3 spinal muscular atrophy genetically confirmed

Age superior or equal to 2 years old up to 30 years of age included

For patients older than 6 years old, willing and able to comply with all protocol requirements and procedures.

For non-ambulant patients, able to sit upright in a wheelchair for at least three hours

Patients over 18 years of age and parent(s)/legal guardian(s) of patients < 18 years of age must provide written informed consent prior to participating in the study and informed assent will be obtained from minors at least 7 years of age when required by regulation.

In France only: Affiliated to or a beneficiary of a social security category

EXCLUSION CRITERIA

Previously treated with an investigational drug within 6 months prior the recruitment in this study.

Other condition which may significantly interfere with the assessment of the SMA and is clearly not related to the disease

Current or anticipated participation in any therapeutic investigational clinical studies.

Patients with specific contraindication to MRI (i.e. metallic foreign body, claustrophobia, and others deemed to be prohibitive by the investigators) will be allowed to participate, but MRI will not be performed.